ARTV
Artiva Biotherapeutics, Inc. Common Stock
NASDAQ: ARTV · HEALTHCARE · BIOTECHNOLOGY
$10.24
+17.43% today
Updated 2026-04-30
Market cap
$255.08M
P/E ratio
—
P/S ratio
8.11x
EPS (TTM)
$-3.43
Dividend yield
—
52W range
$1 – $15
Volume
0.3M
Artiva Biotherapeutics, Inc. Common Stock (ARTV) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $2.00M | $4.93M | $33.49M | $251000.00 | $0.00 |
| Revenue growth (YoY) | — | — | +146.3% | +579.2% | -99.3% | -100.0% |
| Cost of revenue | — | — | — | — | — | $2.60M |
| Gross profit | — | $2.00M | $4.93M | $33.49M | $251000.00 | $-2.60M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | — |
| R&D | $13.85M | $42.41M | $43.98M | $50.25M | $50.33M | $69.54M |
| SG&A | $4.43M | $12.86M | $20.78M | $13.91M | $17.20M | $20.27M |
| Operating income | $-18.27M | $-53.27M | $-59.83M | $-30.67M | $-67.28M | $-90.61M |
| Operating margin | — | -2660.9% | -1213.3% | -91.6% | -26805.6% | — |
| EBITDA | $-17.52M | $-71.58M | $-58.67M | $-28.41M | $-64.85M | $-88.01M |
| EBITDA margin | — | -3575.3% | -1189.8% | -84.8% | -25837.1% | — |
| EBIT | $-17.59M | $-71.83M | $-59.83M | $-30.67M | $-67.28M | $-90.61M |
| Interest expense | $199000.00 | $0.00 | — | — | — | — |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-17.99M | $-71.83M | $-58.39M | $-27.70M | $-58.49M | $-83.86M |
| Net income growth (YoY) | — | -299.2% | +18.7% | +52.6% | -111.2% | -43.4% |
| Profit margin | — | -3587.7% | -1184.1% | -82.7% | -23304.0% | — |